Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (7)

1

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

enthalten in: The lancet / Oncology | March 2020

von Garassino, M. | Gadgeel, S. | Esteban, E. | +16

2

HER2-targeted therapy influences CTC status in metastatic breast cancer

enthalten in: Breast cancer research and treatment | 2020 May 20

von Deutsch, T. | Riethdorf, S. | Fremd, C. | +9

3

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study : evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

enthalten in: European journal of cancer | January 2018

von Schneeweiss, A. | Chia, S. | Hickish, T. | +6

4

First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction

enthalten in: Journal of clinical oncology | February 8, 2016

von Gertz, M. | Landau, H. | Comenzo, R. | +11

5

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer : results from AVADO

enthalten in: European journal of cancer | 15 July 2011

von Pivot, X. | Schneeweiss, A. | Verma, S. | +8

6

Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer

enthalten in: Molecular cancer research | 8 September 2010

von Ceppi, P. | Mudduluru, G. | Kumarswamy, R. | +4

7

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

enthalten in: Journal of clinical oncology | July 10 2010

von Miles, D. | Chan, A. | Dirix, L. | +13

1
[1]